New 8K On June 12, 2017, OWC Pharmaceutical Resea
Post# of 15624
(Total Views: 931)
Posted On: 06/15/2017 6:47:48 AM
New 8K
On June 12, 2017, OWC Pharmaceutical Research Corp. (the "Registrant"
accepted the resignation of Shmuel De-Saban as Chief Financial Officer of the Registrant and its wholly-owned Israeli subsidiary, One World Cannabis Ltd, positions he has held since his appointment in June 2014. In Mr. De-Saban's letter of resignation, a copy of which is attached as Exhibit 17.5 hereto, Mr. De-Saban stated that "the reason for my resignation is to permit me to pursue other business interests. I have had no disagreements with the operations, policies or practices of the Registrant or its subsidiary."
The Registrant anticipates appointing a new CFO on or about July 1, 2017, until which date Mr. Mordechai Bignitz, who is the Registrant's CEO and Chairman and is also a CPA and accountant by education and training, will serve as Interim CFO.
On June 12, 2017, OWC Pharmaceutical Research Corp. (the "Registrant"
accepted the resignation of Shmuel De-Saban as Chief Financial Officer of the Registrant and its wholly-owned Israeli subsidiary, One World Cannabis Ltd, positions he has held since his appointment in June 2014. In Mr. De-Saban's letter of resignation, a copy of which is attached as Exhibit 17.5 hereto, Mr. De-Saban stated that "the reason for my resignation is to permit me to pursue other business interests. I have had no disagreements with the operations, policies or practices of the Registrant or its subsidiary." The Registrant anticipates appointing a new CFO on or about July 1, 2017, until which date Mr. Mordechai Bignitz, who is the Registrant's CEO and Chairman and is also a CPA and accountant by education and training, will serve as Interim CFO.
(0)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼